The first peak occurred early during infection, over days 3–7 post-challenge (CSG IL1 and IL6), while the second wave occurred during acute symptomatic infection over days 10–14 post-challenge (CSGs IL2, IL3, IL7–IL10). This evidence concerns the gene IL3 and infection.